Hannah Johnson Roberts, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Chemoembolization, Therapeutic | 1 | 2021 | 128 | 0.710 |
Why?
|
X-Ray Therapy | 1 | 2016 | 8 | 0.550 |
Why?
|
Paintings | 1 | 2016 | 102 | 0.480 |
Why?
|
Radiosurgery | 2 | 2022 | 1330 | 0.420 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2022 | 2330 | 0.400 |
Why?
|
Lymphopenia | 2 | 2025 | 300 | 0.390 |
Why?
|
Rectal Neoplasms | 3 | 2025 | 1183 | 0.360 |
Why?
|
Radiation Oncology | 1 | 2016 | 572 | 0.340 |
Why?
|
Liver Neoplasms | 2 | 2022 | 4357 | 0.320 |
Why?
|
Neoadjuvant Therapy | 5 | 2025 | 2902 | 0.280 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2024 | 1759 | 0.210 |
Why?
|
Pancreatic Neoplasms | 3 | 2024 | 5446 | 0.200 |
Why?
|
Students, Medical | 1 | 2015 | 1965 | 0.190 |
Why?
|
Curriculum | 1 | 2015 | 3786 | 0.190 |
Why?
|
Collagen Type I | 1 | 2024 | 617 | 0.180 |
Why?
|
Dementia | 1 | 2015 | 2741 | 0.180 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 4054 | 0.180 |
Why?
|
Cholangiocarcinoma | 1 | 2024 | 561 | 0.150 |
Why?
|
Bile Duct Neoplasms | 1 | 2024 | 614 | 0.150 |
Why?
|
Posters as Topic | 1 | 2016 | 6 | 0.140 |
Why?
|
Folklore | 1 | 2016 | 7 | 0.140 |
Why?
|
Medicine in Literature | 1 | 2016 | 32 | 0.130 |
Why?
|
Radium | 1 | 2016 | 70 | 0.130 |
Why?
|
Urothelium | 1 | 2016 | 275 | 0.120 |
Why?
|
Neoplasms, Second Primary | 1 | 2022 | 1061 | 0.120 |
Why?
|
Feasibility Studies | 1 | 2023 | 5311 | 0.100 |
Why?
|
Cystectomy | 1 | 2016 | 603 | 0.100 |
Why?
|
Neoplasm Staging | 2 | 2024 | 11217 | 0.100 |
Why?
|
Leucovorin | 2 | 2024 | 644 | 0.100 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3944 | 0.090 |
Why?
|
Fluorouracil | 2 | 2024 | 1652 | 0.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 11872 | 0.080 |
Why?
|
History, 20th Century | 1 | 2016 | 2765 | 0.080 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6550 | 0.070 |
Why?
|
Carcinoma | 1 | 2016 | 2326 | 0.060 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2016 | 2186 | 0.060 |
Why?
|
Gallium Radioisotopes | 1 | 2024 | 195 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5389 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2025 | 81659 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 2 | 2025 | 6513 | 0.040 |
Why?
|
Humans | 13 | 2025 | 767040 | 0.040 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2024 | 1788 | 0.040 |
Why?
|
Pancreatectomy | 1 | 2023 | 825 | 0.040 |
Why?
|
Prognosis | 3 | 2025 | 29963 | 0.040 |
Why?
|
Mice, Nude | 1 | 2024 | 3618 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13491 | 0.040 |
Why?
|
Cell Line, Tumor | 2 | 2024 | 17097 | 0.040 |
Why?
|
Cell Communication | 1 | 2024 | 1660 | 0.030 |
Why?
|
Fibrosis | 1 | 2024 | 2078 | 0.030 |
Why?
|
Prospective Studies | 1 | 2021 | 54886 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2024 | 36582 | 0.030 |
Why?
|
Treatment Outcome | 4 | 2024 | 65295 | 0.030 |
Why?
|
Propensity Score | 1 | 2023 | 1971 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2024 | 2702 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2024 | 3227 | 0.030 |
Why?
|
Male | 6 | 2025 | 364203 | 0.030 |
Why?
|
Aged | 5 | 2025 | 171319 | 0.030 |
Why?
|
Adult | 4 | 2025 | 223317 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2538 | 0.030 |
Why?
|
Middle Aged | 5 | 2025 | 223233 | 0.020 |
Why?
|
Female | 5 | 2025 | 396660 | 0.020 |
Why?
|
Survival Rate | 1 | 2024 | 12823 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2024 | 5332 | 0.020 |
Why?
|
Young Adult | 1 | 2015 | 59980 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2024 | 59548 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3611 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 9532 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2024 | 8628 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2022 | 2666 | 0.020 |
Why?
|
Neoplasms | 1 | 2016 | 22350 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2025 | 6360 | 0.020 |
Why?
|
Age Factors | 1 | 2023 | 18401 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6844 | 0.020 |
Why?
|
Liver | 1 | 2022 | 7578 | 0.020 |
Why?
|
Boston | 1 | 2016 | 9360 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12069 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2024 | 39317 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12536 | 0.010 |
Why?
|
Algorithms | 1 | 2022 | 14098 | 0.010 |
Why?
|
Signal Transduction | 1 | 2024 | 23621 | 0.010 |
Why?
|
Risk Assessment | 1 | 2022 | 24299 | 0.010 |
Why?
|
Disease Progression | 1 | 2016 | 13646 | 0.010 |
Why?
|
Mice | 1 | 2024 | 81912 | 0.010 |
Why?
|
Time Factors | 1 | 2016 | 40154 | 0.010 |
Why?
|
United States | 1 | 2022 | 72971 | 0.010 |
Why?
|
Animals | 1 | 2024 | 168965 | 0.010 |
Why?
|
Risk Factors | 1 | 2016 | 74886 | 0.010 |
Why?
|